- Home
- QLYS vs LEGN Comparison
QLYS vs LEGN Comparison
Compare QLYS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | LEGN |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.9B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QLYS | LEGN |
|---|---|---|
| Price | $187.20 | $20.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $133.08 | $61.33 |
| AVG Volume (30 Days) | 685.7K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.99 | N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $321,607,000.00 | N/A |
| Revenue This Year | $9.97 | $42.68 |
| Revenue Next Year | $7.15 | $30.52 |
| P/E Ratio | $64.28 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $74.51 | $16.24 |
| 52 Week High | $201.54 | $37.50 |
Technical Indicators
Market Signals| Indicator | QLYS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 47.38 |
| Support Level | $130.78 | $20.70 |
| Resistance Level | $199.13 | $21.97 |
| Average True Range (ATR) | 7.21 | 1.01 |
| MACD | -1.35 | 0.18 |
| Stochastic Oscillator | 60.71 | 36.76 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.